Free Trial!
Today’s Best Stocks To Trade! Click Here
To receive our complimentary newsletters please copy and paste http://www.emergingmarketsllc.com in to your web browser. On the upper right hand corner of the homepage enter your email address and click sign up. You will receive a confirmation email, click the link and your free subscription will be active.
MGI PHARMA, INC. closed at $40.00 up $6.55 (19.58%) with volume of 50,032,240 MGI PHARMA, INC. (NASDAQ:MOGN - News), a biopharmaceutical company focused in oncology and acute care, yesterday provided a summary of the Dacogen (decitabine) for Injection presentations made during the American Society of Hematology (ASH) 49th Annual Meeting and Exposition. Dacogen was the subject of five oral presentations, 11 poster presentations, and four publications. A survival analysis of the five-day outpatient regimen of Dacogen in patients with myelodysplastic syndromes (MDS) and preliminary results from a multicenter, phase 2 study evaluating the five-day regimen of Dacogen in patients with de novo or secondary MDS were among the data presented. Data from a phase 2 trial evaluating Dacogen in older patients with acute myelogenous leukemia (AML) were also presented at the conference.
About MGI PHARMA, INC.
MGI PHARMA, INC., a biopharmaceutical company, engages in the discovery, acquisition, development, and commercialization of proprietary pharmaceutical products in the areas of oncology and acute care in the United States. Its products include Aloxi injection for the prevention of chemotherapy-induced nausea and vomiting (CINV); Dacogen for Injection, for the treatment of patients with myelodysplastic syndrome; Gliadel Wafer for the treatment of malignant glioma, and recurrent glioblastoma multiforme; Salagen Tablets, a treatment for the symptoms of xerostomia induced by radiation therapy in head and neck cancer patients; and Hexalen capsules for the treatment of ovarian cancer. The company's products in various phases of clinical trials comprise Aquavan Injection for sedation of patients undergoing diagnostic or surgical procedures; Aloxi Injection for the prevention of post operative nausea and vomiting; Aloxi Oral Capsule Formulation for the prevention of CINV; Saforis Powder for oral suspension; Amolimogene bepiplasmid to enhance the natural immune response of a patient infected with human papillomavirus; ZYC300, an encapsulated plasmid; Irofulven for chemotherapy treatment of cancer; PARP inhibitor compounds; and glutamate carboxypeptidase II for the prevention and treatment of chemotherapy-induced neuropathy. MGI PHARMA markets its products through direct sales force in the United States and through alliances with other pharmaceutical or biotechnology companies internationally. The company was founded in 1979 as Molecular Genetics, Inc. and changed its name to MGI PHARMA, Inc. in 1990. MGI PHARMA is headquartered in Bloomington, Minnesota.
WCI Communities, Inc. closed at $4.81 up $.76 (18.77%) with volume of 2,883,415 WCI Communities, Inc. (NYSE:WCI - News), a leading builder of traditional and tower residences in highly amenitized lifestyle communities, yesterday reported that the limited waiver of performance that was previously granted by its banks has now been extended to January 7, 2008. On November 7, 2007, the Company initially obtained a limited waiver of performance under the Fixed Charge Coverage covenant of the Senior Secured Revolving Credit Agreement (Credit Facility), and the Term Loan Agreement (Term Loan), and this waiver was originally set to expire on December 7, 2007. During the extended waiver timeframe, we expect to finalize discussions regarding the anticipated longer-term amendment that would provide financial flexibility, including modification of the fixed charges coverage covenant, and obtain approval of lenders participating in these facilities.
About WCI Communities, Inc.
WCI Communities, Inc., together with its subsidiaries, operates as an integrated homebuilding and real estate services company. The company's activities primarily include single- and multi-family (traditional) homebuilding, and mid- and high-rise (tower) homebuilding, as well as the provision of real estate services primarily in Florida. It designs, constructs, and operates leisure-oriented and master-planned communities; and designs, builds, and sells traditional homes serving primary, second, and retirement home buyers. WCI Communities also designs, builds, and sells luxury residential towers and condominium hotels targeted to primary and affluent, leisure-oriented home purchasers. Its real estate services include realty brokerage, title insurance and closing services, and mortgage banking services. In addition, the company develops and operates amenity facilities, sells selected land parcels, and enters into real estate joint ventures. WCI Communities also has operations in New York, New Jersey, Connecticut, Massachusetts, Virginia, and Maryland. As of December 31, 2006, it had 79 locations where it builds single-family and multi-family homes or mid-rise and high-rise residential units, or operating amenity facilities. The company was founded in 1946 and is headquartered in Bonita Springs, Florida.
Source Interlink Companies, Inc. closed at $3.20 up $.66 (25.98%) with volume of 1,636,663 The editors of Motor Trend, part of SOURCE INTERLINK MEDIA, announced today the selection of the Chevrolet Corvette as the winner of The Editors' Coolest Car Challenge: from Sixty-Four Cars to One, presented by XM Satellite Radio. The Editors' Coolest Car Challenge invited readers of leading titles Motor Trend and Automobile Magazine to match their automotive wits against the editors. Using an NCAA-style tournament bracket, readers selected from 64 XM-equipped vehicles, which were pitted against one another to try to guess which vehicle would match the editors' choice for Coolest Car. The Corvette came out on top.
About Source Interlink Companies, Inc.
Source Interlink Companies, Inc. operates as a marketing, merchandising, and fulfillment company of entertainment products in North America. Its entertainment products include DVDs, music CDs, magazines, books, and related items. The company engages in the distribution and fulfillment of entertainment products to retail chains and direct-to-consumers through the Internet; import and export of periodicals sold in approximately 100 markets worldwide; and co-ordination of product selection and placement for impulse items sold at checkout counters. It also involves in processing and collection of rebate claims, as well as management of sales data obtained at the point-of-purchase; design, manufacture, and installation of wire fixtures and custom wood displays in retail chains. The company's customers include bookstore chains, music stores, other specialty retailers, grocery stores, drug stores, and mass merchandise retailers. In addition, Source Interlink provides print and digital media content to the enthusiast community. Its magazine content portfolio comprises 76 enthusiast magazine titles, 90 related Web sites, approximately 65 events, 2 television programs, 1 radio program, and approximately 400 branded products. As of August 1, 2007, Source Interlink served approximately 110,000 retail store locations. The company was founded in 1988 and is headquartered in Bonita Springs, Florida.
Cardica, Inc. closed at $10.83 up $2.50 (30.01%) with volume of 2,098,713 Cardica, Inc. (Nasdaq: CRDC - News) today announced the partial exercise of the over-allotment option granted to the underwriters of Cardica's November 2007 underwritten public offering. The underwriters exercised their option to purchase 481,170 shares of common stock from Cardica at a purchase price of $8.00 per share.
About Cardica, Inc.
Cardica, Inc. designs and manufactures proprietary automated anastomotic systems used by surgeons to perform coronary artery bypass surgery. The company's products include C-Port Distal Anastomosis System, which is designed to perform an end-to-side distal anastomosis by attaching the end of a bypass vein graft to a coronary artery downstream of an occlusion or narrowing; C-Port xA Distal Anastomosis System, an enhanced C-Port system, which includes a change from a spring-driven to a gas release-driven stapling mechanism, as well as incorporates non-traumatic vessel clamps and safety mechanisms; and C-Port Flex A Anastomosis System, which includes modifications to the C-Port xA system that are designed to enable automated anastomoses to be performed as part of minimally invasive and robot-facilitated CABG procedures. Its products also comprise PAS-Port Proximal Anastomosis System, an automated device used to perform an end-to-side proximal anastomosis between a saphenous vein and the aorta. In addition, the company develops the Cook Vascular Closure Device to be used in interventional vascular procedures. Cardica has an agreement with Cook Incorporated for the development of the Cook Vascular Closure Device, as well as to develop and commercialize a specialized device to close the PFO. It primarily sells the C-Port systems in the United States and Europe, and the PAS-Port systems in Europe and in Japan through distributors. The company was founded in 1997 as Vascular Innovations, Inc. and changed its name to Cardica, Inc. in 2001. Cardica is headquartered in Redwood City, California.
About Emerging Markets Consulting, LLC Emerging Markets Consulting, LLC is an investor relations and consulting firm serving carefully selected micro cap and small cap clients. Services available include turnkey investor relations services, consulting, marketing and related services needed by publicly traded companies. EMC is unique in that they only work with companies after a stringent due diligence process and they also work with a limited number of clients in order to provide service that is exceptional. The above referenced companies are not clients of Emerging Markets and no compensation has been paid for the exposure provided by this report.
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned. Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited.
Please remember to go to www.emergingmarketsllc.com and enter your email address to sign up for our free newsletter.
CONTACT: Emerging Markets Consulting, LLC Tel: +1 321 206 6682 e-mail: jamespainter@emergingmarketsllc.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
